NL301089I2 - imlifidase - Google Patents
imlifidase Download PDFInfo
- Publication number
- NL301089I2 NL301089I2 NL301089C NL301089C NL301089I2 NL 301089 I2 NL301089 I2 NL 301089I2 NL 301089 C NL301089 C NL 301089C NL 301089 C NL301089 C NL 301089C NL 301089 I2 NL301089 I2 NL 301089I2
- Authority
- NL
- Netherlands
- Prior art keywords
- imlifidase
- ides polypeptide
- medicament
- disease
- prevention
- Prior art date
Links
- 229950009631 imlifidase Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/2201—Streptopain (3.4.22.10)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0511769A GB0511769D0 (en) | 2005-06-09 | 2005-06-09 | Treatment |
| GB0605781A GB0605781D0 (en) | 2006-03-22 | 2006-03-22 | Treatment |
| PCT/EP2006/005454 WO2006131347A2 (en) | 2005-06-09 | 2006-06-08 | Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL301089I1 NL301089I1 (cg-RX-API-DMAC7.html) | 2021-01-20 |
| NL301089I2 true NL301089I2 (nl) | 2021-02-04 |
Family
ID=36952007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL301089C NL301089I2 (nl) | 2005-06-09 | 2021-01-14 | imlifidase |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8133483B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1901773B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5427409B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105770871A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE548049T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006256891B2 (cg-RX-API-DMAC7.html) |
| BE (1) | BE2021C505I2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2611646C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2380950T3 (cg-RX-API-DMAC7.html) |
| FR (1) | FR21C1004I2 (cg-RX-API-DMAC7.html) |
| NL (1) | NL301089I2 (cg-RX-API-DMAC7.html) |
| PL (1) | PL1901773T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1901773E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006131347A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002216863B8 (en) * | 2000-12-21 | 2008-03-20 | Id Biomedical Corporation | Streptococcus pyogenes antigens and corresponding DNA fragments |
| US8691544B2 (en) | 2007-05-04 | 2014-04-08 | Glycorex Transplantation Ab | Material for separation of a biomolecule |
| CN101903401B (zh) | 2007-12-21 | 2013-06-05 | 罗切格利卡特公司 | 抗体的稳定性试验 |
| ES2535963T3 (es) | 2009-02-09 | 2015-05-19 | Roche Glycart Ag | Análisis del patrón de glicosilación de inmunoglobulina |
| US8673606B2 (en) * | 2009-04-22 | 2014-03-18 | Ofir Menashe | Microorganism comprising particles and uses of same |
| GB201413240D0 (en) * | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502305D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502306D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| SG11201806639VA (en) | 2016-02-04 | 2018-09-27 | Genovis Ab | New streptococcal proteases |
| US20210228738A1 (en) * | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| JP7668261B2 (ja) * | 2019-08-01 | 2025-04-24 | メモリアル スローン ケタリング キャンサー センター | 改良された免疫療法のための細胞およびその使用 |
| SG11202110968VA (en) | 2019-12-06 | 2021-10-28 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
| CA3182893A1 (en) | 2020-05-08 | 2021-11-11 | Regeneron Pharmaceuticals, Inc. | Vegf traps and mini-traps and methods for treating ocular disorders and cancer |
| GB202007434D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Methods |
| GB202007431D0 (en) | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Cysteine protease |
| JP2023541698A (ja) * | 2020-09-21 | 2023-10-03 | 上海宝済薬業有限公司 | 組合せ医薬及びその使用 |
| JP2023545731A (ja) | 2020-10-07 | 2023-10-31 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | 肢帯型２ｉ（ｌｇｍｄ２ｉ）を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質（ｆｋｒｐ）の治療的アデノ随伴ウイルス送達 |
| JP2024515626A (ja) | 2021-04-16 | 2024-04-10 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン |
| EP4079848A1 (en) | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
| JP2024547125A (ja) * | 2021-12-22 | 2024-12-26 | 上海宝済薬業股▲ふん▼有限公司 | 免疫グロブリン分解酵素ＩｄｅＥの変異体の用途 |
| CN115998690B (zh) * | 2022-11-10 | 2024-07-26 | 上海泰昶生物技术有限公司 | 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺 |
| KR20250123949A (ko) | 2022-11-18 | 2025-08-18 | 사이즈믹 테라퓨틱, 인코포레이티드. | Fc 융합 분자 및 이의 용도 |
| WO2024148276A1 (en) | 2023-01-06 | 2024-07-11 | Seismic Therapeutic, Inc. | Protease variants and uses thereof |
| WO2025030053A1 (en) * | 2023-08-01 | 2025-02-06 | Insmed Incorporated | Novel igg proteases and methods of use thereof |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001261585B2 (en) * | 2000-05-12 | 2006-08-31 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
| GB0123400D0 (en) * | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| GB0130228D0 (en) * | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
-
2006
- 2006-06-08 AT AT06754207T patent/ATE548049T1/de active
- 2006-06-08 JP JP2008515137A patent/JP5427409B2/ja active Active
- 2006-06-08 US US11/921,770 patent/US8133483B2/en active Active
- 2006-06-08 ES ES06754207T patent/ES2380950T3/es active Active
- 2006-06-08 EP EP06754207A patent/EP1901773B1/en active Active
- 2006-06-08 PT PT06754207T patent/PT1901773E/pt unknown
- 2006-06-08 WO PCT/EP2006/005454 patent/WO2006131347A2/en not_active Ceased
- 2006-06-08 CN CN201610049256.0A patent/CN105770871A/zh active Pending
- 2006-06-08 CA CA2611646A patent/CA2611646C/en active Active
- 2006-06-08 PL PL06754207T patent/PL1901773T3/pl unknown
- 2006-06-08 AU AU2006256891A patent/AU2006256891B2/en active Active
-
2021
- 2021-01-14 NL NL301089C patent/NL301089I2/nl unknown
- 2021-02-04 FR FR21C1004C patent/FR21C1004I2/fr active Active
- 2021-02-09 BE BE2021C505C patent/BE2021C505I2/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT1901773E (pt) | 2012-06-06 |
| PL1901773T3 (pl) | 2012-09-28 |
| US8133483B2 (en) | 2012-03-13 |
| EP1901773B1 (en) | 2012-03-07 |
| FR21C1004I1 (cg-RX-API-DMAC7.html) | 2021-03-26 |
| WO2006131347A3 (en) | 2007-05-31 |
| CN105770871A (zh) | 2016-07-20 |
| JP5427409B2 (ja) | 2014-02-26 |
| FR21C1004I2 (fr) | 2022-01-14 |
| EP1901773A2 (en) | 2008-03-26 |
| US20100303781A1 (en) | 2010-12-02 |
| BE2021C505I2 (cg-RX-API-DMAC7.html) | 2021-05-31 |
| ES2380950T3 (es) | 2012-05-21 |
| WO2006131347A2 (en) | 2006-12-14 |
| JP2008542418A (ja) | 2008-11-27 |
| AU2006256891B2 (en) | 2011-08-04 |
| CA2611646C (en) | 2015-08-11 |
| ATE548049T1 (de) | 2012-03-15 |
| NL301089I1 (cg-RX-API-DMAC7.html) | 2021-01-20 |
| AU2006256891A1 (en) | 2006-12-14 |
| CA2611646A1 (en) | 2006-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301089I2 (nl) | imlifidase | |
| WO2008071418A3 (en) | Use of the endoglycosidase endos for treating immunoglobulin g mediated diseases | |
| TW200626171A (en) | Fixed dosing of HER antibodies | |
| CY1115871T1 (el) | Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας | |
| EA201000903A1 (ru) | Антитела к pcrv-антигену pseudomonas aeruginosa | |
| CY1113640T1 (el) | Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας | |
| TW200738270A (en) | Method of treating depression using a TNFα antibody | |
| MX341370B (es) | Antagonistas anti - beta7 humanizados y usos para los mismos. | |
| TW200709817A (en) | Platform antibody compositions | |
| MY181969A (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| MY149630A (en) | Antibodies against amyloid-beta peptide | |
| ECSP099833A (es) | Anticuerpos humanizados contra el globulomero a?(20-42) y sus usos | |
| EP2493506A4 (en) | IL-17A ANTAGONISTS | |
| EA200701918A1 (ru) | Белок липокалин | |
| LT2878297T (lt) | Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai | |
| EA201290557A1 (ru) | Пептидный аналог оксинтомодулина | |
| DK1773885T3 (da) | Humaniserede anti-c-met-antagonister | |
| EP2579894A4 (en) | Cgrp antibodies | |
| BRPI0506771A (pt) | anticorpo, e, composição farmacêutica | |
| WO2007056457A3 (en) | Methods, compositions, and kits for the treatment of medical conditions | |
| WO2008100805A3 (en) | Anti-robo4 antibodies and uses therefor | |
| DK2109623T3 (da) | Cancerbehandling med anti-IL-1-antistoffer | |
| WO2007073497A3 (en) | Calcium channel antagonists | |
| MA32288B1 (fr) | Nouveaux anticorps utiles pour le traitement du cancer | |
| EA201101241A1 (ru) | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 |